• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    test company saurabh

    PCI Pharma Services

    Alcami

    Baxter BioPharma Solutions

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Aphena Pharma Solutions

    Emergent BioSolutions

    test company saurabh

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    What Happens When the All-Clear Signal is Given?

    Maybe 3M had some good ideas?

    What Happens When the All-Clear Signal is Given?
    Emil W. Ciurczak, DoraMaxx Consulting06.04.20
    About the time this comes to print, most of you will be venturing from your fallout shelters, er, uh, I mean home offices. Living in New York (just north of the city), I have experienced 9/11, Hurricane Sandy, and COVID-19, in just a few decades, so, wherever you live, I can quote Bill Clinton, “I feel your pain.” When I wrote my earlier column, I had no idea that the COVID-19 virus would have the effects it did. I had been considering our on-going trade wars between POTUS and China, Europe, etc., upsets like the Iceland volcano, or preventable incidents, such as 9/11 in 2001. Guess I just got (un)lucky.

    Now, when you do finally re-enter the world, you will need to ask some hard questions about the way you currently do business. Some of which are:
    1. Am I saving enough money with long-distance sourcing to risk complete cut-off in times of trouble? We are seeing lots of potential problems around the world, today.
    2. Are my products so specialized that I cannot interchange another supplier’s materials? This is especially true for medical devices, but not having alternate sources for dosage forms is just as bad; both involve “after-the-fact” product development and validation, while product orders go unfilled. In other words, is the secrecy and peculiarity of each “boutique” supplier worth the lower costs from competition for contracts?
    In the past, I have used gas and liquid chromatography (GC and LC) as examples of technologies suffering from a myriad of cottage industries. One of the reasons that the Food and Drug Agency refused to allow New Drug Applications (NDAs) to use chromatography as a primary analytical method for release of the product was the peculiar nature of each column packing. The paradigm, at that time, for GC columns was to buy a supply (5 gallons) of silicone oil, dissolve a small amount in a solvent and use a Roto-Vap to coat silica gel. We had this particular packing for a year or two, then hoped we could find a similar polymer for our next year or two. It was almost as bad for LC packings—each supplier had proprietary packings, making it nearly impossible to have back-up columns, should your supply be interrupted.

    Spoiler alert: virtually every pharmaceutical product on the market today is analyzed and released by chromatographic methods. How did that happen? Chromatographers began classifying their HPLC packings as compilations of McReynolds constants. For GC, the relative retention times of benzene, ethanol, methyl-ethyl-ketone, nitromethane, and pyridine, were documented, as these solvents represent Lewis acids and bases, polar and non-polar solvents, and unsaturated chemicals. In short, we had a method to standardizing all column packings, meaning we could quickly validate a substitute for a current product, should it be unavailable.

    This is certainly not a novel concept. Spectrometers have been calibrated with standard materials for a century or more. Ultraviolet, visible, near-infrared, and infrared units are all checked for wavelength accuracy by chemicals (liquids, solvents, metallic oxides) supplied by firms, but traceable to an institution (a bureau of standards, N.I.S.T., etc.). When GC and LC suppliers began standardizing technologies, they became the backbone of the industry. So, how did they stay in business, if they weren’t the only source of “column X?” On the fundamentals, used by automobile, lab instrument, and wristwatch suppliers: price, availability, dependability, customer service (for lab instruments, that means applications notes and personnel to assist scientists), and, most importantly, reproducibility. 

    This approach is nothing new. Mr. Ford knew the benefits of interchangeable parts on an assembly line: cost, availability, speed of assembly, etc. One (sad) observation of our industry seems to be a carry-over of 18th century beliefs. “Scientists” believed there was a difference between “chemicals” and “living chemicals.” The difference was smashed when, in 1828, the German chemist, Friedrich Wöhler synthesized urea by treating silver cyanate with ammonium chloride. This was the first time an “organic” compound was artificially synthesized from inorganic starting materials, without the involvement of living organisms.

    In this vein, my experience is that pharmaceutical analysts (as well as most organizations) think they are different from all the rest of chemical industries. When I introduced a 60-year old chemical test for benzalkonium Cl, based on a surfactant assay, my fellow analysts at Sandoz were amazed. Sadly, NO ONE involved in Pharma analysis would ever consider glancing at any analytical text or journal not of their cult. Like organic chemistry before the synthesis of urea, their methods were “different” from mere chemical industries’ methods. Slowly, we are learning to emulate non-Pharma industries. For example, when Ajaz Hussain held the meetings that led to the PAT Guidance (finalized in 2004) in 2002, he had speakers from, in one case, the auto industry to lead seminars and group discussions.

    It seems that just about every other industry had adopted modern production methods while we were firmly planted in the 1960s. I once observed that a person who retired in 1970 could come back to work today and not need much training to be back on the job. Even surfactants were being produced continuously in the 1970s. In Japan, one country had four parallel lines of railroad tanker cars lined up. One contained fatty acid or alcohols, one chlorosulfonic acid (which were reacted in a continuous stream), another with strong caustic (e.g., 50% NaOH) to be used to quench the excess acid and bring the pH to about 9, and the last line of cars to be used to store and ship the finished product. All this while 40 years later, we are still using “batch processing” (or cGMP) methodology to prepare drug products.

    Considering that most solid dosage forms are, in essence, simply mixes of powders, there is really no good justification for the weeks each batch takes to make. Don’t even plead the importance of assuring quality when you only analyze 20 tablets out of every 1-2 million!

    However, since there are no price restrictions or constraints (e.g., the U.S. government negotiating prices for Medicare in all 50 states, not in a piecemeal manner), any inefficiency may be covered by simply raising prices. While generic competition helps, there are few other pressures to reduce prices.

    Of course, the massive potential cost savings from continuous manufacturing (CM) are not the only reason to indulge. A couple of other reasons for convert to CM are:
    1. There is literally no scale-up time from pilot plant to production levels; to increase the size from clinical batches to commercial, simply run the equipment longer.
    2. The pain and time involved in validating a second, third, etc. site is minimized, because any number of test lots may be made to duplicate the critical component parameters, using far less material that attempting to produce full-sized lots to achieve a comparative batch.
    3. If a secondary (or tertiary) supplier of any raw material needed to be tested (primary one not available, for example), the small size of the batches and lack of need for cleaning between batches would allow the needed changes to be made in days, not months. Perhaps, if locally purchased raw materials were used because of a supply-chain breakdown.
    “All this is well and good,” you may say, “but, where does 3M come into the picture and what does that have to do with my product?” I’m glad you asked. As I may have mentioned previously, even though I am a chemist, I find Bloomberg’s Businessweek quite informative. Considering that almost every company makes changes or improvements only when and if they help the bottom line.

    Two weeks ago, Businessweek had a multi-page article about the response of 3M to the COVID-19 pandemic. Being a successful business, they watch for the potential uses for their product. In response to the H1N1 outbreak, 3M read and absorbed the 2006 plan that was put together by Obama’s health advisors that predicted many more and potentially harsher pandemics could and would happen in the future. Sadly, the pandemic response team was disbanded two years ago, but that is water under the bridge. In any case, 3M decided to brace for a potential problem.

    Instead of seeing the Swine Flu dissipating and dismantling their “war setting,” they purchased more mask-making equipment and “moth-balled” it, if and until it might be needed. As the virus spread from Asia to Italy, they hired more people, ramped up production, and most importantly, found local sourcing for materials. They procured textiles and plastics from local sources, hired a large number of workers, all while spacing the equipment such that “social distancing” was, de facto, unavoidable. It is predicted that they will, over the next 10 months, make one billion N-95 masks!

    How would we match that in a Pharma paradigm? Maybe, simply scrapping “just-in-time” would help. IF we switch to continuous manufacturing, all current cGMP companies would be “stuck” with a huge amount of warehouse space since there would be no intermediates to store, nor any final products awaiting final release from QC. What to do with all those empty shelves? Well, shut off the lights, lock the doors and leave them alone.

    Here’s one suggestion: when you see the beginnings of the next world-wide threat (yes, there will be one), be it a political problem (trade war?), volcano, tsunami, or pandemic on the horizon, turn on the lights in the empty warehouses, turn on the heat, hire more people, and order, order, order raw materials. Then, proceed to make enough product to see you through and allow time to find alternate suppliers in an orderly fashion.

    Be like 3M: live long and prosper!


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • Analytical Services

    Related Columns

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Analytical Services | Laboratory Testing
      Re-Open Your Tool Chest

      Re-Open Your Tool Chest

      There’s no longer an excuse NOT to start “PAT-ing” your products
      Emil W. Ciurczak, DoraMaxx Consulting 07.15.19

    • Analytical Services | Laboratory Testing
      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Making a solid case for PAT, QbD and continuous manufacturing in the pharma industry
      Emil W. Ciurczak, DoraMaxx Consulting 03.06.19


    • Analytical Services | Laboratory Testing
      The Great Diaspora of the Pharma Industry

      The Great Diaspora of the Pharma Industry

      Or, good things come in small(er) packages
      Emil W. Ciurczak, DoraMaxx Consulting 11.14.18

    • Analytical Services | Laboratory Testing
      Possibly Time for a New Paradigm

      Possibly Time for a New Paradigm

      Or, why the chicken should cross the road
      Emil W. Ciurczak, DoraMaxx Consulting 10.10.18

    • Analytical Services | Laboratory Testing
      The Times, They Are a-Changin’

      The Times, They Are a-Changin’

      For contract organizations and generics, for sure
      Emil W. Ciurczak, DoraMaxx Consulting 07.20.18


    • Analytical Services | Bioanalytical Services | Laboratory Testing
      The Final Frontier

      The Final Frontier

      A look at contract bioprocessing and PAT/QbD
      Emil W. Ciurczak, DoraMaxx Consulting 06.12.18

    • Analytical Services | Laboratory Testing
      We Need to Get Back to Basics

      We Need to Get Back to Basics

      In life, and the lab, the calculator/computer is a blessing and a curse!
      Emil W. Ciurczak, DoraMaxx Consulting 05.08.18

    • Analytical Services
      Finding the “Missing Link”

      Finding the “Missing Link”

      Outsourcing and the supply chain
      Emil W. Ciurczak, DoraMaxx Consulting 10.11.17


    • Analytical Services | Laboratory Testing
      Analytical Equipment Technology for the 21st Century

      Analytical Equipment Technology for the 21st Century

      A look at some more toys available for CMOs, CROs and generics to boost their analytical capabilities
      Emil W. Ciurczak, DoraMaxx Consulting 05.09.17

    • Analytical Services
      Quality Risk Management

      Quality Risk Management

      It’s not just for the big guys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 04.03.17

    • Analytical Services | R&D
      Trends in Pharma Analysis

      Trends in Pharma Analysis

      A look at how pharma analysis technology continues to evolve to meet market needs
      Emil W. Ciurczak, DoraMaxx Consulting 03.07.17


    • Analytical Services | Drug Development | Laboratory Testing

      Orphan Drug Development & Production: Turning Lemons into Lemonade

      Forming a “win-win-win” paradigm for large pharma companies, contract service providers and generics
      Emil W. Ciurczak, DoraMaxx Consulting 01.26.17

    • Analytical Services | Bioanalytical Services | Chemistry | Laboratory Testing

      Hyperspectral Imaging

      It’s not just for the Big Boys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 11.09.16

    • Analytical Services | Bioanalytical Services | R&D

      Raman Spectroscopy

      Rapidly becoming the CRO/CMO’s best friend
      Emil W. Ciurczak, DoraMaxx Consulting 10.13.16

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • ICON Acquires Medpass
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Arkema Reports Full-year 2020 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Biden Prioritizes PPP Relief for the Beauty Industry
    Christie Brinkley Joins SBLA Beauty
    Madison Reed Raises $52 Million in Financing Round
    Happi

    Latest Breaking News From Happi

    ACI Unveils New Online Resources
    Sales More Than Double at Madison Reed
    PBA Opposes House Bill 2325 in West Virginia
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    S-OneLP adds to growing team
    Avery Dennison expands automotive portfolio
    Amberley Labels turns to Kurz for embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Believe Diapers Launch in U.S.
    Forbes Ranks Rockline Among Best U.S. Employers
    H&V Announces Price Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login